Astria Therapeutics to present at upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
Astra Therapeutics announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on 2 March 2025.
- Markus Magerl MD, Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institute of Allergology, will present the design of the global Phase 3 trial of navenibart in a presentation of poster number 617 titled, “ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).”
- Joshua S Jacobs MD, Medical Director of Allergy and Asthma Clinical Research Inc, will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart in a presentation of poster number 606 titled, “Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.”
- Chunxia Lily Zhao PhD, Director of Antibody Discovery at Astria Therapeutics, will present information on the profile of STAR-0310 in poster number 697 titled, “Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.”
All three presentations will take place in a poster session titled “Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema” beginning at 9:45am Pacific Standard Time on 2 March 2025, in the Convention Center, Ground Level, Hall A.
(Source: Astria)